WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H540112
CAS#: 120011-70-3 (HCl)
Description: Donepezil HCl is a GSK3 and AChE inhibitor and potential σ1 receptor agonist used to treat Alzheimer's disease. It also improves learning and memory, downregulates expression of NR1 subuinit of NMDA receptors, decreases left ventricular end diastolic pressure, and increases left ventricular contractility.
Hodoodo Cat#: H540112
Name: Donepezil HCl
CAS#: 120011-70-3 (HCl)
Chemical Formula: C24H30ClNO3
Exact Mass: 0.00
Molecular Weight: 415.950
Elemental Analysis: C, 69.30; H, 7.27; Cl, 8.52; N, 3.37; O, 11.54
Related CAS #: 120014-06-4 (free base) 120011-70-3 (HCl) 142698-19-9 (R-isomer) 142057-80-5 (S-isomer)
Synonym: Aricept; E-2020; E2020; E 2020; Donepezil HCl
IUPAC/Chemical Name: 2-((1-benzylpiperidin-4-yl)methyl)-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one hydrochloride
InChi Key: XWAIAVWHZJNZQQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H29NO3.ClH/c1-27-22-14-19-13-20(24(26)21(19)15-23(22)28-2)12-17-8-10-25(11-9-17)16-18-6-4-3-5-7-18;/h3-7,14-15,17,20H,8-13,16H2,1-2H3;1H
SMILES Code: O=C1C(CC2CCN(CC3=CC=CC=C3)CC2)CC4=C1C=C(OC)C(OC)=C4.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2933.39.9100
More Info:
| Biological target: | Donepezil is an AChE inhibitor for bAChE and hAChE with IC50 of 8.12 nM and 11.6 nM , respectively. |
| In vitro activity: | The effect of donepezil, a drug used for treatment of Alzheimer's disease, on oxaliplatin-induced peripheral neuropathy was investigated in vitro. Donepezil effectively attenuated oxaliplatin- and cisplatin-induced inhibition of neurite outgrowth in cultured PC12 cells. Moreover, donepezil did not inhibit the anti-tumor activity of oxaliplatin in any cultured cancer cell line. These results suggested that donepezil attenuated oxaliplatin-induced peripheral neuropathy without impairing anticancer efficacy. Reference: J Pharmacol Sci. 2019 Jul;140(3):291-294. https://www.sciencedirect.com/science/article/pii/S1347861319356816?via%3Dihub |
| In vivo activity: | The efficacy of donepezil in enhancing remyelination in vivo was examined in the cuprizone-induced demyelination model. Adult female C57BL/6 mice were fed a diet that contained 0.2% (w/w) cuprizone for 5 weeks, followed by standard chow feeding with a daily intraperitoneal injection of donepezil (1.5 or 5 mg/kg) or vehicle for 1–3 weeks (Fig. 5a). The myelin status in the corpus callosum region was measured by Luxol fast blue staining. Five-week cuprizone treatment induced the complete loss of myelin in the corpus callosum as indicated by the loss of blue staining (Fig. 5b). Reference: Acta Pharmacol Sin. 2019 Nov;40(11):1386-1393. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888883/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| Water | 19.7 | 47.39 | |
| DMSO | 3.6 | 8.65 | |
| DMF | 1.0 | 2.40 | |
| Ethanol | 1.0 | 2.40 | |
| PBS (pH 7.2) | 0.5 | 1.20 |
The following data is based on the product molecular weight 415.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019 Jul;140(3):291-294. doi: 10.1016/j.jphs.2019.05.009. Epub 2019 Jul 19. PMID: 31377017. 2. Cui X, Guo YE, Fang JH, Shi CJ, Suo N, Zhang R, Xie X. Donepezil, a drug for Alzheimer's disease, promotes oligodendrocyte generation and remyelination. Acta Pharmacol Sin. 2019 Nov;40(11):1386-1393. doi: 10.1038/s41401-018-0206-4. Epub 2019 Mar 27. PMID: 30918344; PMCID: PMC6888883. |
| In vitro protocol: | 1. Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019 Jul;140(3):291-294. doi: 10.1016/j.jphs.2019.05.009. Epub 2019 Jul 19. PMID: 31377017. 2. Cui X, Guo YE, Fang JH, Shi CJ, Suo N, Zhang R, Xie X. Donepezil, a drug for Alzheimer's disease, promotes oligodendrocyte generation and remyelination. Acta Pharmacol Sin. 2019 Nov;40(11):1386-1393. doi: 10.1038/s41401-018-0206-4. Epub 2019 Mar 27. PMID: 30918344; PMCID: PMC6888883. |
| In vivo protocol: | 1. Kawashiri T, Shimizu S, Shigematsu N, Kobayashi D, Shimazoe T. Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect. J Pharmacol Sci. 2019 Jul;140(3):291-294. doi: 10.1016/j.jphs.2019.05.009. Epub 2019 Jul 19. PMID: 31377017. 2. Cui X, Guo YE, Fang JH, Shi CJ, Suo N, Zhang R, Xie X. Donepezil, a drug for Alzheimer's disease, promotes oligodendrocyte generation and remyelination. Acta Pharmacol Sin. 2019 Nov;40(11):1386-1393. doi: 10.1038/s41401-018-0206-4. Epub 2019 Mar 27. PMID: 30918344; PMCID: PMC6888883. |
1: Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:41-9. PubMed PMID: 15496222; PubMed Central PMCID: PMC1884553.
2: Reyes JF, Preskorn SH, Khan A, Kumar D, Cullen EI, Perdomo CA, Pratt RD. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:50-7. PubMed PMID: 15496223; PubMed Central PMCID: PMC1884550.
3: Li Q, Chen M, Liu H, Yang L, Yang G. Expression of APP, BACE1, AChE and ChAT in an AD model in rats and the effect of donepezil hydrochloride treatment. Mol Med Rep. 2012 Dec;6(6):1450-4. doi: 10.3892/mmr.2012.1102. Epub 2012 Sep 26. PubMed PMID: 23023803.
4: Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI, Pratt RD. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:25-33. PubMed PMID: 15496220; PubMed Central PMCID: PMC1884554.
5: Liew KB, Tan YT, Peh KK. Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer's disease patients. Drug Dev Ind Pharm. 2015 Apr;41(4):583-93. doi: 10.3109/03639045.2014.884130. Epub 2014 Feb 5. PubMed PMID: 24495273.
6: Rojanasthien N, Aunmuang S, Hanprasertpong N, Roongapinun S, Teekachunhatean S. Bioequivalence study of donepezil hydrochloride tablets in healthy male volunteers. ISRN Pharmacol. 2012;2012:527679. doi: 10.5402/2012/527679. Epub 2012 Nov 1. PubMed PMID: 23209934; PubMed Central PMCID: PMC3503324.
7: Tiseo PJ, Vargas R, Perdomo CA, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:51-5. PubMed PMID: 9839767; PubMed Central PMCID: PMC1873809.
8: Yang B, Hou Q, Hu F, Zhang F. [Total flavones derived from Lagotis brevituba maxim reduce the levels of inflammatory cytokines in cerebral cortex and hippocampus of Alzheimer's disease mice]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Jul;32(7):881-5. Chinese. PubMed PMID: 27363265.
9: Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:30-4. PubMed PMID: 9839763; PubMed Central PMCID: PMC1873808.
10: Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:40-4. PubMed PMID: 9839765; PubMed Central PMCID: PMC1873815.
11: Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:45-50. PubMed PMID: 9839766; PubMed Central PMCID: PMC1873807.
12: Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:25-9. PubMed PMID: 9839762; PubMed Central PMCID: PMC1873814.
13: Nagy CF, Kumar D, Cullen EI, Bolton WK, Marbury TC, Gutierrez MJ, Hutman HW, Pratt RD. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol. 2004 Nov;58 Suppl 1:18-24. PubMed PMID: 15496219; PubMed Central PMCID: PMC1884552.
14: Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:1-6. PubMed PMID: 9839758; PubMed Central PMCID: PMC1873812.
15: Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:35-9. PubMed PMID: 9839764; PubMed Central PMCID: PMC1873816.
16: Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:7-12. PubMed PMID: 9839759; PubMed Central PMCID: PMC1873811.
17: Tiseo PJ, Foley K, Friedhoff LT. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:56-60. PubMed PMID: 9839768; PubMed Central PMCID: PMC1873817.
18: Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):169-77. PubMed PMID: 12611746.
19: Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:13-8. PubMed PMID: 9839760; PubMed Central PMCID: PMC1873813.
20: Knopman DS. Management of cognition and function: new results from the clinical trials programme of Aricept(R) (donepezil HCl). Int J Neuropsychopharmacol. 2000 Jul;3(7):13-20. PubMed PMID: 11343620.
